The Latest Breaking News from Medicare

A Senate deal to cap the cost of insulin at $35 a month for individuals with private insurance and Medicare poses a new test of whether Democrats can make good on campaign pledges to rein in drug costs, Axios' Adriel Bettelheim writes.

Medical clinics are flagging doctor burnout and financial reasons for the changes, which will mean out-of-pocket expenses for many people.

Rising rates are a headwind for most stocks. However, for a handful, they are leading to an earnings boom,. Here are 3 stocks benefitting from higher rates: Humana (HUM), Everest RE (RE), and Silvercrest Asset Management (SAMG).

Poverty is a political choice. The new Labor government must raise jobseeker payments to protect our most vulnerable

Medicare could have saved $3.6 billion in a single year if it had bought generic drugs from Mark Cuban’s online pharmacy, according to a Harvard University report.

WASHINGTON — Two key senators on Wednesday released a widely anticipated bill aimed at lowering insulin prices and capping monthly copays under commercial and Medicare insurance plans.

The bill would cap insulin copays at the lesser of $35 or 25 percent of the list price per month in commercial and Medicare Part D plans.

TPG Capital, private equity, has agreed to acquire Convey Health Solutions Holdings Inc (NYSE:CNVY) for $10.50 per share in cash, representing an enterprise value of approximately $1.1 billion. The purchase price represents approximately 99% over Convey's 30-day volume-weighted average price per share as of June 17 and a premium of approximately 143% to…

The Supreme Court decides in favor of an insurer in a case focused on reimbursement rates for kidney dialysis.

The federal government is undervaluing general practices around the country, according to a doctor who says cost pressures are pushing patients to hospital emergency departments.

Sometimes good news comes with a cloudy lining.